Goldman sach is laying people off. Their coverage on company is going to be changing. According to, “Citigroup are among the companies that will be suspended while Boston Scientific Corp. and Agilent Technologies are among the companies being dropped from coverage.”

That mean investor have last information from GS to cover this company. Biotech and Pharma is difficult to analyze even with outside-analyst (i.e. GS). Now it is going to be more difficult to make a good decision on biotech and phara industry.